import os, json, base64
from io import BytesIO
from pptx import Presentation
from pptx.util import Inches, Pt
from pptx.enum.shapes import MSO_SHAPE
from pptx.enum.text import PP_ALIGN, MSO_ANCHOR
from pptx.dml.color import RGBColor
from pptx.enum.dml import MSO_THEME_COLOR

ROOT = '/tmp/workspace/sodium-valproate-ppt'
OUT = ROOT + '/output/Sodium_Valproate_Drug_Presentation.pptx'
ASSET = ROOT + '/assets/fetched_image.json'

prs = Presentation()
prs.slide_width = Inches(10)
prs.slide_height = Inches(7.5)
blank = prs.slide_layouts[6]

NAVY = RGBColor(18, 56, 93)
BLUE = RGBColor(31, 112, 179)
TEAL = RGBColor(33, 142, 132)
PALE = RGBColor(235, 245, 252)
LIGHT = RGBColor(247, 250, 252)
TEXT = RGBColor(29, 42, 54)
MUTED = RGBColor(94, 110, 126)
RED = RGBColor(185, 57, 57)
AMBER = RGBColor(205, 130, 22)
WHITE = RGBColor(255,255,255)

# utilities
def set_fill(sh, color):
    sh.fill.solid(); sh.fill.fore_color.rgb = color
    sh.line.fill.background()

def add_text(slide, x,y,w,h, text, size=20, color=TEXT, bold=False, align=PP_ALIGN.LEFT, font='Aptos', valign=MSO_ANCHOR.TOP):
    tb = slide.shapes.add_textbox(Inches(x), Inches(y), Inches(w), Inches(h))
    tf = tb.text_frame; tf.clear(); tf.word_wrap=True
    tf.margin_left=tf.margin_right=tf.margin_top=tf.margin_bottom=0
    tf.vertical_anchor=valign
    lines = text.split('\n')
    for idx,line in enumerate(lines):
        p = tf.paragraphs[0] if idx==0 else tf.add_paragraph()
        p.text=line; p.alignment=align
        p.space_after=Pt(2)
        for r in p.runs:
            r.font.name=font; r.font.size=Pt(size); r.font.bold=bold; r.font.color.rgb=color
    return tb

def add_bullets(slide, items, x=.7, y=1.65, w=8.65, h=4.95, size=20, color=TEXT):
    tb=slide.shapes.add_textbox(Inches(x),Inches(y),Inches(w),Inches(h)); tf=tb.text_frame; tf.clear(); tf.word_wrap=True
    tf.margin_left=Inches(.08); tf.margin_right=Inches(.03); tf.margin_top=Inches(.02); tf.margin_bottom=0
    for i,item in enumerate(items):
        p=tf.paragraphs[0] if i==0 else tf.add_paragraph()
        p.text=item; p.level=0; p.font.size=Pt(size); p.font.name='Aptos'; p.font.color.rgb=color
        p.space_after=Pt(10); p.bullet=True
    return tb

def base(slide, title, number=None):
    bg=slide.background.fill; bg.solid(); bg.fore_color.rgb=WHITE
    band=slide.shapes.add_shape(MSO_SHAPE.RECTANGLE, Inches(0), Inches(0), Inches(10), Inches(.2)); set_fill(band,NAVY)
    add_text(slide,.55,.36,8.7,.65,title,27,NAVY,True)
    line=slide.shapes.add_shape(MSO_SHAPE.RECTANGLE, Inches(.55), Inches(1.15), Inches(8.9), Inches(.04)); set_fill(line,BLUE)
    if number:
        add_text(slide,9.15,7.1,.45,.2,str(number),9,MUTED,False,PP_ALIGN.RIGHT)
    add_text(slide,.55,7.08,7.3,.2,'Sodium valproate | educational presentation',8,MUTED)

def card(slide,x,y,w,h,heading,body,accent=BLUE,body_size=16):
    sh=slide.shapes.add_shape(MSO_SHAPE.ROUNDED_RECTANGLE,Inches(x),Inches(y),Inches(w),Inches(h)); set_fill(sh,LIGHT)
    sh.line.color.rgb=RGBColor(209,224,235)
    strip=slide.shapes.add_shape(MSO_SHAPE.RECTANGLE,Inches(x),Inches(y),Inches(.09),Inches(h)); set_fill(strip,accent)
    add_text(slide,x+.28,y+.18,w-.42,.35,heading,16,accent,True)
    add_text(slide,x+.28,y+.65,w-.42,h-.8,body,body_size,TEXT)

def warning(slide, text):
    sh=slide.shapes.add_shape(MSO_SHAPE.ROUNDED_RECTANGLE, Inches(.6), Inches(6.45), Inches(8.8), Inches(.42)); set_fill(sh,RGBColor(255,244,230))
    add_text(slide,.8,6.54,8.4,.2,text,10,RED,True,PP_ALIGN.CENTER)

def add_molecule(slide, x,y,w,h):
    try:
        data=json.load(open(ASSET))[0]
        raw=base64.b64decode(data['base64'].split(',',1)[1])
        slide.shapes.add_picture(BytesIO(raw),Inches(x),Inches(y),width=Inches(w),height=Inches(h))
    except Exception:
        add_text(slide,x,y,w,h,'Chemical structures\nnot available',16,MUTED,False,PP_ALIGN.CENTER,valign=MSO_ANCHOR.MIDDLE)

def circle(slide, x,y,d,label,color):
    s=slide.shapes.add_shape(MSO_SHAPE.OVAL,Inches(x),Inches(y),Inches(d),Inches(d)); set_fill(s,color)
    add_text(slide,x+.12,y+.18,d-.24,d-.3,label,14,WHITE,True,PP_ALIGN.CENTER,valign=MSO_ANCHOR.MIDDLE)

# 1
s=prs.slides.add_slide(blank); s.background.fill.solid(); s.background.fill.fore_color.rgb=NAVY
add_text(s,.75,1.42,8.5,.7,'Sodium Valproate',34,WHITE,True,PP_ALIGN.CENTER)
add_text(s,1.15,2.42,7.7,.9,'Broad-spectrum antiseizure medicine\nMood stabilizer with important safety considerations',19,RGBColor(216,235,249),False,PP_ALIGN.CENTER)
# molecular motif
for i,c in enumerate([TEAL,BLUE,RGBColor(110,170,211),TEAL]):
    circle(s,1.2+i*2.05,4.45,.9,['Na+','GABA','CNS','ASM'][i],c)
for i in range(3):
    ln=s.shapes.add_shape(MSO_SHAPE.RECTANGLE,Inches(2.05+i*2.05),Inches(4.87),Inches(1.15),Inches(.06)); set_fill(ln,RGBColor(151,204,233))
add_text(s,.75,6.75,8.5,.25,'Pharmacology presentation | Use current local prescribing guidance for clinical decisions',10,RGBColor(200,222,237),False,PP_ALIGN.CENTER)

# 2
s=prs.slides.add_slide(blank); base(s,'Sodium valproate - Molecular structure',2)
add_molecule(s,1.05,1.65,7.9,3.9)
add_text(s,.75,5.82,8.5,.35,'Valproic acid, sodium valproate and divalproex deliver the active valproate ion.',15,TEXT,False,PP_ALIGN.CENTER)
card(s,1.75,6.28,6.5,.47,'Key chemistry','Short-chain branched fatty acid; highly protein-bound.',TEAL,11)

# 3
s=prs.slides.add_slide(blank); base(s,'Drug classification',3)
card(s,.75,1.65,4.05,1.55,'Pharmacological class','Broad-spectrum antiseizure medication (ASM)\nAlso known as: valproate / valproic acid',BLUE,16)
card(s,5.15,1.65,4.05,1.55,'CNS role','Anticonvulsant and mood stabilizer\nMultiple neuronal actions',TEAL,16)
card(s,.75,3.65,4.05,1.55,'Available forms','Oral immediate-release, delayed-release and extended-release products; IV preparations in some settings.',AMBER,15)
card(s,5.15,3.65,4.05,1.55,'Clinical identity','A versatile ASM, but reproductive and organ-toxicity risks strongly influence selection.',RED,15)
warning(s,'Formulations and brand-switching policies vary. Prescribe by current local guidance.')

# 4
s=prs.slides.add_slide(blank); base(s,'Mechanism of action',4)
add_text(s,.72,1.45,8.6,.45,'The precise contribution of each mechanism is uncertain; combined actions reduce neuronal excitability.',15,MUTED,False,PP_ALIGN.CENTER)
circle(s,.75,2.25,1.55,'↑ GABA\navailability',TEAL)
circle(s,3.0,2.25,1.55,'Na+ channel\nmodulation',BLUE)
circle(s,5.25,2.25,1.55,'T-type Ca2+\nchannel effects',RGBColor(113,142,183))
circle(s,7.5,2.25,1.55,'↓ repetitive\nfiring',NAVY)
for x in [2.32,4.57,6.82]:
    add_text(s,x,2.72,.55,.3,'→',24,BLUE,True,PP_ALIGN.CENTER)
card(s,1.0,4.65,8.0,1.05,'Clinical consequence','Broad-spectrum activity across generalized and focal seizure types. Mechanisms are multifactorial rather than a single receptor effect.',BLUE,16)

# 5
s=prs.slides.add_slide(blank); base(s,'Pharmacokinetics',5)
add_bullets(s,[
    'Well absorbed orally; bioavailability is generally high. Food can delay absorption and may improve gastrointestinal tolerability.',
    'Highly protein bound. The free fraction rises when binding becomes saturated or albumin is low, so total concentrations can be misleading.',
    'Extensive hepatic metabolism, mainly glucuronidation and mitochondrial beta-oxidation; metabolites are excreted in urine.',
    'Half-life and concentration vary with age, formulation, dose and interacting antiseizure medicines.'
],.75,1.55,8.45,4.7,18)
warning(s,'Use clinical response and toxicity, not a number alone, when interpreting drug concentrations.')

# 6
s=prs.slides.add_slide(blank); base(s,'Indications',6)
card(s,.72,1.55,4.2,1.55,'Epilepsy','Generalized tonic-clonic, absence, myoclonic and atonic seizures; also used for focal-onset seizures. IV valproate may be used in selected status epilepticus protocols.',BLUE,15)
card(s,5.08,1.55,4.2,1.55,'Bipolar disorder','Acute mania and mixed states in appropriately selected patients. Maintenance choices depend on the individual.',TEAL,15)
card(s,.72,3.55,4.2,1.55,'Migraine prevention','Used in some jurisdictions, but pregnancy-related restrictions are particularly important. Not for acute migraine treatment.',AMBER,15)
card(s,5.08,3.55,4.2,1.55,'Individualize selection','Seizure syndrome, comorbidity, interactions and pregnancy potential determine whether it is appropriate.',RED,15)
warning(s,'Licensed indications differ by country and formulation.')

# 7
s=prs.slides.add_slide(blank); base(s,'Dose and administration',7)
add_bullets(s,[
    'Initiation and dose changes should be directed by a specialist or experienced prescriber; titrate according to indication, formulation, response and adverse effects.',
    'A commonly used starting approach for epilepsy is 10-15 mg/kg/day, increased gradually. Product labels may permit up to 60 mg/kg/day in selected patients.',
    'Some immediate or delayed-release products are divided doses; extended-release products may be once daily. Do not crush modified-release products.',
    'Do not stop suddenly unless medically necessary: abrupt withdrawal can precipitate seizures or relapse.'
],.75,1.48,8.45,4.85,17)
warning(s,'Doses shown are teaching examples only. Verify the exact product label and local protocol.')

# 8
s=prs.slides.add_slide(blank); base(s,'Common adverse effects',8)
card(s,.72,1.5,2.02,1.7,'Neurologic','Tremor\nSedation\nDizziness\nAtaxia',BLUE,16)
card(s,2.95,1.5,2.02,1.7,'Gastrointestinal','Nausea\nVomiting\nDyspepsia\nAbdominal pain',TEAL,16)
card(s,5.18,1.5,2.02,1.7,'Metabolic','Weight gain\nAppetite change\nMenstrual/endocrine effects',AMBER,15)
card(s,7.41,1.5,2.02,1.7,'Other','Transient alopecia\nThinning hair\nRash (uncommon)',RGBColor(113,142,183),15)
card(s,1.25,4.02,7.5,1.12,'Practical point','Adverse effects are often dose-related. New tremor, marked somnolence, bruising or persistent vomiting needs prompt assessment.',RED,17)

# 9
s=prs.slides.add_slide(blank); base(s,'Contraindications and precautions',9)
add_bullets(s,[
    'Significant hepatic disease or previous valproate-associated hepatic dysfunction.',
    'Known urea-cycle disorders and certain mitochondrial disorders, especially POLG-related disease, because of severe toxicity risk.',
    'History of valproate-associated pancreatitis, or unexplained severe hyperammonemia.',
    'Bleeding disorders, thrombocytopenia, low albumin, obesity/metabolic concerns, and older age require individualized assessment.',
    'Pregnancy potential requires strict risk assessment and regulatory safeguards.'
],.75,1.45,8.45,4.95,17)
warning(s,'Check the current product label for absolute contraindications in your country.')

# 10
s=prs.slides.add_slide(blank); base(s,'Drug interactions',10)
card(s,.7,1.48,4.15,1.55,'Lamotrigine','Valproate inhibits lamotrigine metabolism. Use lower lamotrigine doses and slow titration to reduce serious rash risk.',RED,15)
card(s,5.13,1.48,4.15,1.55,'Enzyme inducers','Carbamazepine, phenytoin, phenobarbital and primidone can lower valproate concentrations. Interaction effects may be bidirectional.',BLUE,15)
card(s,.7,3.52,4.15,1.55,'CNS and bleeding risk','Alcohol and sedating drugs add CNS depression. Aspirin/anticoagulants may increase bleeding concerns and need review.',AMBER,15)
card(s,5.13,3.52,4.15,1.55,'Other important pairs','Topiramate raises hyperammonemia/encephalopathy concern. Cannabidiol may increase liver enzyme elevations.',TEAL,15)
warning(s,'Always review prescribed medicines, non-prescription products and alcohol use.')

# 11
s=prs.slides.add_slide(blank); base(s,'Serious toxicity: recognize early',11)
card(s,.68,1.48,2.75,2.0,'Hepatotoxicity','Risk is highest early in treatment. Watch for malaise, lethargy, anorexia, vomiting, jaundice or loss of seizure control.',RED,15)
card(s,3.62,1.48,2.75,2.0,'Pancreatitis','Severe or persistent abdominal pain with nausea/vomiting requires urgent evaluation; discontinue if confirmed.',AMBER,15)
card(s,6.56,1.48,2.75,2.0,'Hyperammonemia','May occur despite normal liver tests. Consider if lethargy, vomiting, hypothermia or altered mental state develops.',TEAL,15)
card(s,1.3,4.2,7.35,1.15,'Hematologic toxicity','Thrombocytopenia and coagulation abnormalities can present with easy bruising, bleeding or petechiae. Check FBC and coagulation when clinically indicated.',BLUE,16)
warning(s,'These symptoms warrant prompt medical assessment, not self-adjustment of treatment.')

# 12
s=prs.slides.add_slide(blank); base(s,'Monitoring',12)
card(s,.7,1.42,2.6,3.6,'Before starting','• Weight/BMI\n• Full blood count\n• Liver function tests\n• Coagulation screen\n• Pregnancy and reproductive-risk assessment\n• Review interactions and history',BLUE,15)
card(s,3.7,1.42,2.6,3.6,'Early therapy','• Clinical adverse-effect review\n• LFTs periodically, especially first 6 months\n• Assess adherence and seizure/mood control\n• Check ammonia if symptoms suggest encephalopathy',TEAL,15)
card(s,6.7,1.42,2.6,3.6,'Stable treatment','• FBC and LFTs at intervals per local policy\n• Weight/BMI\n• Drug concentration only for selected questions: toxicity, adherence, interactions or loss of control',AMBER,15)
warning(s,'Monitoring schedules vary. Follow local policy and the product information.')

# 13
s=prs.slides.add_slide(blank); base(s,'Pregnancy and reproductive safety',13)
add_text(s,.78,1.4,8.45,.55,'Valproate can cause major congenital malformations and adverse neurodevelopmental outcomes after in-utero exposure.',19,RED,True,PP_ALIGN.CENTER)
card(s,.75,2.18,4.05,2.25,'People who can become pregnant','Avoid unless no suitable alternative is effective/tolerated. Follow national pregnancy-prevention requirements, effective contraception and specialist review.',RED,16)
card(s,5.18,2.18,4.05,2.25,'Planning pregnancy or pregnancy suspected','Do not stop antiseizure treatment abruptly. Seek urgent specialist advice to balance fetal risks against uncontrolled seizures or illness.',AMBER,16)
card(s,1.45,4.9,7.1,.75,'Counselling','Document shared decision-making, discuss contraception and preconception planning, and review treatment regularly.',TEAL,16)
warning(s,'Regulatory restrictions have changed in several countries. Check current national safety guidance.')

# 14
s=prs.slides.add_slide(blank); base(s,'Key exam points',14)
add_bullets(s,[
    'Valproate is a broad-spectrum ASM, particularly useful for generalized seizure syndromes including absence and myoclonic seizures.',
    'Major adverse effects: weight gain, tremor, gastrointestinal upset, alopecia, thrombocytopenia and hyperammonemia.',
    'High-yield serious risks: hepatotoxicity, pancreatitis, encephalopathy and major fetal harm.',
    'Critical interaction: valproate increases lamotrigine exposure and rash risk.',
    'Monitor liver function, blood count, weight and clinical toxicity; measure ammonia when encephalopathy is suspected.'
],.75,1.5,8.45,4.95,18)

# 15 mechanism visual
s=prs.slides.add_slide(blank); base(s,'Mechanism - visual recap',15)
add_text(s,1.0,1.48,8,.35,'Valproate increases inhibitory tone and limits excessive synchronized neuronal firing.',18,TEXT,False,PP_ALIGN.CENTER)
circle(s,1.0,2.35,1.6,'GABA\n↑ inhibition',TEAL)
circle(s,4.2,2.35,1.6,'VALPROATE\nmultimodal',NAVY)
circle(s,7.4,2.35,1.6,'↓ seizure\npropagation',BLUE)
add_text(s,2.7,2.9,1.0,.3,'→',30,BLUE,True,PP_ALIGN.CENTER)
add_text(s,5.9,2.9,1.0,.3,'→',30,BLUE,True,PP_ALIGN.CENTER)
card(s,1.15,5.0,7.7,.8,'Channel actions','Sodium and calcium-channel effects also help reduce repetitive firing. The overall mechanism is not fully explained by one pathway.',BLUE,15)

# 16 safety visual
s=prs.slides.add_slide(blank); base(s,'Safety flags',16)
for x,head,body,col in [(.62,'LIVER','Nausea, lethargy, anorexia, jaundice',RED),(2.95,'PANCREAS','Abdominal pain, nausea, vomiting',AMBER),(5.28,'AMMONIA','Confusion, vomiting, somnolence',TEAL),(7.61,'BLEEDING','Bruising, petechiae, prolonged bleeding',BLUE)]:
    sh=s.shapes.add_shape(MSO_SHAPE.ROUNDED_RECTANGLE,Inches(x),Inches(1.8),Inches(1.78),Inches(3.5)); set_fill(sh,LIGHT); sh.line.color.rgb=col
    circle(s,x+.43,2.15,.92,'!',col)
    add_text(s,x+.16,3.35,1.45,.35,head,14,col,True,PP_ALIGN.CENTER)
    add_text(s,x+.16,3.82,1.45,.98,body,13,TEXT,False,PP_ALIGN.CENTER)
warning(s,'Potentially serious symptoms require assessment. Do not advise patients to abruptly stop treatment.')

# 17
s=prs.slides.add_slide(blank); base(s,'Sodium valproate - Quick visual recap',17)
for x,head,body,col in [(0,'CLASS','Broad-spectrum\nASM',BLUE),(2.5,'MAIN USE','Generalized\nseizures',TEAL),(5,'KEY RISKS','Liver, pancreas,\npregnancy',RED),(7.5,'MONITOR','LFT, FBC,\nclinical status',AMBER)]:
    sh=s.shapes.add_shape(MSO_SHAPE.ROUNDED_RECTANGLE,Inches(x),Inches(1.75),Inches(2.5),Inches(3.35)); set_fill(sh,LIGHT); sh.line.color.rgb=RGBColor(210,225,235)
    add_text(s,x+.18,2.2,2.14,.38,head,15,col,True,PP_ALIGN.CENTER)
    add_text(s,x+.18,3.05,2.14,1.0,body,18,TEXT,True,PP_ALIGN.CENTER)
add_text(s,.7,5.8,8.6,.45,'Choose only after balancing clinical benefit against individualized safety and reproductive risks.',17,NAVY,True,PP_ALIGN.CENTER)

# 18 references
s=prs.slides.add_slide(blank); base(s,'References',18)
add_bullets(s,[
    'Katzung BG. Basic and Clinical Pharmacology, 16th ed. Chapter: Antiseizure Drugs. (Valproate: chemistry, clinical uses and pharmacokinetics.)',
    'Harrison’s Principles of Internal Medicine, 22nd ed. Table 66-9: common antiseizure drugs and adverse effects.',
    'U.S. Food and Drug Administration. Depakote (divalproex sodium) Prescribing Information, accessed September 2026.',
    'NHS Specialist Pharmacy Service. Valproic acid and sodium valproate monitoring, accessed September 2026.',
    'Local/national prescribing information and pregnancy-prevention regulations should be checked before clinical use.'
],.72,1.5,8.55,4.9,17)
add_text(s,.75,6.38,8.5,.35,'Educational use only. This deck does not replace specialist advice, a local protocol or the current approved product label.',11,RED,True,PP_ALIGN.CENTER)

prs.save(OUT)
print(OUT)